

Matthew C Abramowitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3656208/publications.pdf>

Version: 2024-02-01

50
papers

1,144
citations

567281

15
h-index

395702

33
g-index

50
all docs

50
docs citations

50
times ranked

2180
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy. <i>European Urology Oncology</i> , 2022, 5, 304-313.	5.4	12
2	Levels of Evidence for Radiation Therapy Recommendations in the National Comprehensive Cancer Network (NCCN) Clinical Guidelines. <i>Advances in Radiation Oncology</i> , 2022, 7, 100832.	1.2	4
3	Clinicogenomic characterization of prostate cancer liver metastases. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 366-369.	3.9	7
4	A Single Axial Slice of the Sternocleidomastoids and Paravertebral Muscles Associated with Worse Local Progression-Free Survival and Severe Toxicity in Sarcopenic Head and Neck Cancer Patients Undergoing Radiotherapy. <i>Cureus</i> , 2022, 14, e22463.	0.5	2
5	Diagnosis and treatment of metastatic prostate cancer. , 2022, , 23-47.		0
6	Repeatability of CBCT radiomic features and their correlation with CT radiomic features for prostate cancer. <i>Medical Physics</i> , 2021, 48, 2386-2399.	3.0	13
7	Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy. <i>Journal of Urology</i> , 2021, 205, 1344-1351.	0.4	5
8	Opioid use patterns in patients with head and neck cancer receiving radiation therapy: Single-institution retrospective analysis characterizing patients who did not require opioid therapy. <i>Head and Neck</i> , 2021, 43, 2973-2984.	2.0	2
9	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). <i>Cancer Genetics</i> , 2021, 258-259, 61-68.	0.4	2
10	Assessment of CT to CBCT contour mapping for radiomic feature analysis in prostate cancer. <i>Scientific Reports</i> , 2021, 11, 22737.	3.3	7
11	Margin verification for hypofractionated prostate radiotherapy using a novel dose accumulation workflow and iterative CBCT. <i>Physica Medica</i> , 2020, 77, 154-159.	0.7	11
12	The role of radiomics in prostate cancer radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 900-912.	2.0	24
13	Phase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 305-315.	0.8	20
14	Segmentation of prostate and prostate zones using deep learning. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 932-942.	2.0	36
15	Towards a universal MRI atlas of the prostate and prostate zones. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 121-130.	2.0	9
16	Local Treatment in Metastatic Prostate Cancer: A Cultural Shift Confronts Power and Selection. <i>European Urology</i> , 2019, 75, 419-422.	1.9	1
17	Acute Epithelial Toxicity Is Prognostic for Improved Prostate Cancer Response to Radiation Therapy: A Retrospective, Multicenter, Cohort Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 957-963.	0.8	5
18	Assessment of Rigid Registration Quality Measures in Ultrasound-Guided Radiotherapy. <i>IEEE Transactions on Medical Imaging</i> , 2018, 37, 428-437.	8.9	8

#	ARTICLE	IF	CITATIONS
19	Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. <i>JAMA Oncology</i> , 2018, 4, e175230.	7.1	65
20	Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. <i>European Urology</i> , 2018, 74, 99-106.	1.9	28
21	Contemporary role of postoperative radiotherapy for prostate cancer. <i>Translational Andrology and Urology</i> , 2018, 7, 399-413.	1.4	5
22	Automatic Detection of Prostate Tumor Habitats using Diffusion MRI. <i>Scientific Reports</i> , 2018, 8, 16801.	3.3	8
23	Assessment of specific versus combined purpose knowledge based models in prostate radiotherapy. <i>Journal of Applied Clinical Medical Physics</i> , 2018, 19, 209-216.	1.9	8
24	Magnetic resonance imaging (MRI)-based radiomics for prostate cancer radiotherapy. <i>Translational Andrology and Urology</i> , 2018, 7, 445-458.	1.4	26
25	An Automated Multiparametric MRI Quantitative Imaging Prostate Habitat Risk Scoring System for Defining External Beam Radiation Therapy Boost Volumes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 821-829.	0.8	16
26	Optimal timing of post-prostatectomy radiotherapy for prostate cancer with high-risk pathologic features: A multi-institutional analysis. <i>Journal of Clinical Oncology</i> , 2018, 36, 24-24.	1.6	0
27	Dynamic contrast-enhanced MRI for automatic detection of foci of residual or recurrent disease after prostatectomy. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 13-21.	2.0	4
28	Automatic Detection and Quantitative DCE-MRI Scoring of Prostate Cancer Aggressiveness. <i>Frontiers in Oncology</i> , 2017, 7, 259.	2.8	12
29	Ethnic heterogeneity and prostate cancer mortality in Hispanic/Latino men: a population-based study. <i>Oncotarget</i> , 2017, 8, 69709-69721.	1.8	30
30	Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy. <i>Journal of Clinical Oncology</i> , 2017, 35, 9-9.	1.6	0
31	Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy. <i>Journal of Clinical Oncology</i> , 2017, 2017, 9-9.	1.6	0
32	Head and neck second primary cancer rates in the human papillomavirus era: A population-based analysis. <i>Head and Neck</i> , 2016, 38, E873-83.	2.0	26
33	Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. <i>Radiotherapy and Oncology</i> , 2016, 121, 294-298.	0.6	22
34	Quantification of the margin required for treating intraprostatic lesions. <i>Journal of Applied Clinical Medical Physics</i> , 2016, 17, 304-312.	1.9	4
35	Weighing the Addition of Androgen Suppression Therapy to Radiotherapy Dose Escalation for Intermediate-Risk Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1715-1717.	1.6	9
36	Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy: A Multi-Institutional Observational Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 1046-1053.	0.8	47

#	ARTICLE	IF	CITATIONS
37	Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2016, 34, 3648-3654.	1.6	296
38	Moderate hypofractionated radiotherapy "not yet a standard of care. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 655-656.	27.6	3
39	Feasibility and Initial Dosimetric Findings for a Randomized Trial Using Dose-Painted Multiparametric Magnetic Resonance Imaging-Defined Targets in Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 827-834.	0.8	10
40	Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies. <i>Oncotarget</i> , 2016, 7, 53362-53376.	1.8	90
41	Neoadjuvant Radiotherapy Improves Survival in Patients With T2b/T3 Bladder Cancer: A Population-Based Analysis. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 378-384.e1.	1.9	5
42	A meta-analysis of health-related quality of life after primary treatment for prostate cancer as measured by the Expanded Prostate Cancer Index Composite. <i>Journal of Clinical Oncology</i> , 2015, 33, 39-39.	1.6	1
43	Ethnicity and Clinical Outcomes in Head and Neck Cancer: an Analysis of the SEER Database. <i>Journal of Racial and Ethnic Health Disparities</i> , 2014, 1, 267-274.	3.2	17
44	Bladder Carcinoma. <i>Medical Radiology</i> , 2014, , 377-386.	0.1	1
45	Concurrent Radiotherapy with Carboplatin and Cetuximab for the Treatment of Medically Compromised Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2014, 4, 165.	2.8	5
46	Active surveillance vs. treatment for low-risk prostate cancer: A cost comparison. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 576-580.	1.6	54
47	Hypofractionated radiotherapy for prostate cancer: has the time come?. <i>Oncology</i> , 2012, 26, 519, 522.	0.5	0
48	Dermal Lymphatic Invasion and Inflammatory Breast Cancer Are Independent Predictors of Outcome After Postmastectomy Radiation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 30-33.	1.3	12
49	The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. <i>Cancer</i> , 2008, 112, 55-60.	4.1	156
50	Postprostatectomy Radiation Therapy for Prostate Cancer. <i>Seminars in Radiation Oncology</i> , 2008, 18, 15-22.	2.2	16